Bayer has halted its late-stage human clinical trials of experimental uterine fibroids treatment vilaprisan. The company said it was a "precautionary measure", taken after receiving the results of long-term toxicology studies involving rodents. Bayer said it expected peak February 24, 2014 sales of €1bn ($1.1 billion) from vilaprisan.
Bayer has halted its late-stage human clinical trials of experimental uterine fibroids treatment vilaprisan. The company said it was a "precautionary measure", taken after receiving the results of long-term toxicology studies involving rodents. Bayer said it expected peak annual sales of €1bn ($1.1 billion) from vilaprisan.